4.8 Article

KrasG12D induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells

Journal

ONCOGENE
Volume 35, Issue 29, Pages 3880-3886

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.437

Keywords

-

Funding

  1. Wilhelm-Sander Foundation [2012.084.1]
  2. Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/1-2, SCHN 959/2-1, GE2289/1, SI 1549/2-1, SFB824]
  3. Deutsche Krebshilfe [110908, 111273, 109992]
  4. NIH [NIHP30 DK050306, NIH R01DK060694]

Ask authors/readers for more resources

Epidermal growth factor receptor (EGFR) signaling has a critical role in oncogenic Kras-driven pancreatic carcinogenesis. However, the downstream targets of this signaling network are largely unknown. We developed a novel model system utilizing murine primary pancreatic ductal epithelial cells (PDECs), genetically engineered to allow time-specific expression of oncogenic Kras(G12D) from the endogenous promoter. We show that primary PDECs are susceptible to Kras(G12D)-driven transformation and form pancreatic ductal adenocarcinomas in vivo after Cdkn2a inactivation. In addition, we demonstrate that activation of Kras(G12D) induces an EGFR signaling loop to drive proliferation. Interestingly, pharmacological inhibition of EGFR fails to decrease Kras(G12D)-activated ERK or PI3K signaling. Instead our data provide novel evidence that EGFR signaling is needed to activate the oncogenic and pro-proliferative transcription factor c-MYC. EGFR and c-MYC have been shown to be essential for pancreatic carcinogenesis. Importantly, our data link both pathways and thereby explain the crucial role of EGFR for Kras(G12D)-driven carcinogenesis in the pancreas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available